We value your privacy

We use cookies to offer you a better browsing experience and analyse our website performance. We also use third-party cookies to further customise your experience showing relevant content while you are navigating on third-party platforms.

Learn more

Our Priorities International

Back to the Priorities

Country Focus

Medical technology companies operate in diverse global markets. Specific insights on regulatory, ethical and procurement environment are essential to expanding to new markets.

MedTech Europe has established several specific country focus groups that deal with market access, barriers to trade, regulatory convergence, ethics and compliance considerations. These groups address local laws, standards, and requirements that affect the industry in a specific country, such as restrictions on medical devices imports, discriminatory procurement rules, and price controls.

Country focus groups are currently established for China, India, Brazil, Turkey, Switzerland, the United Kingdom, the Eurasian Economic Union, and Middle East & Africa.

Key topics

International Collaborations

International regulators, standards and policy-making bodies play a central role in shaping global healthcare. MedTech Europe engages with stakeholders and decision-makers around the world on issues of common interest.

Global Health Policy

Through our advocacy efforts, technical expertise, and holistic approach, MedTech Europe actively engages on many international issues of relevance for the medical technology sector.

Trade & Customs

As a global industry, trade negotiations and customs rules play an important role in bringing medical technologies to customers and patients around the world. MedTech Europe is actively engaged in trade and customs issues at European and international level.

Brexit

Brexit is a critical topic for the medical technology industry which has developed highly complex ties between the United Kingdom (UK) and the rest of the EU. Medical technologies are often moved between different EU countries during their production lifecycle and their clinical use. Crucially, up to 30% of our industry’s products have been authorised via UK Notified Bodies (CE marking) and could lose such authorisation overnight in the case of a “cliff edge” Brexit. MedTech Europe is tracking developments closely and has produced a position paper and other relevant documents to help medical technology companies to navigate Brexit.